Crossmark

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

Crossref DOI link: https://doi.org/10.1186/s40425-019-0569-1

Published Online: 2019-03-29

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ascierto, Paolo A.

Capone, Mariaelena

Grimaldi, Antonio M.

Mallardo, Domenico

Simeone, Ester

Madonna, Gabriele

Roder, Heinrich

Meyer, Krista

Asmellash, Senait

Oliveira, Carlos

Roder, Joanna

Grigorieva, Julia https://orcid.org/0000-0001-8136-6167
License Information

Text and Data Mining valid from 2019-03-29
More Information

Article History

Received: 9 December 2018

Accepted: 15 March 2019

First Online: 29 March 2019

Ethics approval and consent to participate

: The study was approved by the Ethics Committee of the Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale” with registration number 35/16 and all patients signed informed consent for the use of biological samples for research purposes.

: Not applicable.

: P.A: Consulting or Advisory Role for BMS, Roche-Genentech, MSD, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, Newlink Genetics, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs; Research funds from BMS, Roche-Genentech, Array; Travel support by MSD.A.G.: Consulting or Advisory Role for BMS, MSD, Novartis; Travel support by BMS, MSD, Merck Serono, Roche.HR, JR, JG, KM, SA, CO are or were full time employees of Biodesix and have/had stock options of the company.Other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.